Comparison of circulating MMP-9, TIMP-1 and CA19-9 in the detection of pancreatic cancer

Maiken Thyregod Jørgensen; Nils Brunner; Ove B. Schaffalitzky de Muckadell

Comparison of circulating MMP-9, TIMP-1 and CA19-9 in the detection of pancreatic cancer

Maiken Thyregod Jørgensen, Nils Brunner, Ove B. Schaffalitzky de Muckadell

33 Citations (Scopus)

Abstract

Background/Aim: The performance of the circulating tumor markers carbohydrate antigen 19-9 (CA19-9), matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of metalloproteinase 1 (TIMP-1) were evaluated separately and in combination for their potential value in detecting pancreatic ductal adenocarcinoma. Patients and Methods: The patients had symptoms of pancreatic cancer. The discriminative strength of MMP-9 and TIMP-1 were compared to that of CA19-9 using receiver operating characteristics curves, area under the curves (AUC), specificity and sensitivity. Results: The sensitivities of MMP-9, TIMP-1 and CA19-9 in detecting pancreatic ductal adenocarcinoma were 58.82%, 47.1% and 86%, respectively, with specificities of 34.6%, 692% and 73%. The AUCs of MMP-9, TIMP-1 and CA19-9 were 050, 0.64 and 0.84, respectively. Combining the three markers did not significantly improve detection of pancreatic ductal adenocarcinoma compared to CA19-9 used alone. Conclusion: Circulating MMP-9 and TIMP-1 were inferior to CA19-9 as markers for detecting pancreatic ductal adenocarcinoma and did not improve the diagnostic accuracy when combined with CA19-9.

Original language	English
Journal	Anticancer Research
Volume	30
Pages (from-to)	587-592
Number of pages	6
ISSN	0250-7005
Publication status	Published - Feb 2010

Keywords

Former LIFE faculty

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{9f64716f950d43a8aede7ce44066f951,

title = "Comparison of circulating MMP-9, TIMP-1 and CA19-9 in the detection of pancreatic cancer",

abstract = "Background/Aim: The performance of the circulating tumor markers carbohydrate antigen 19-9 (CA19-9), matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of metalloproteinase 1 (TIMP-1) were evaluated separately and in combination for their potential value in detecting pancreatic ductal adenocarcinoma. Patients and Methods: The patients had symptoms of pancreatic cancer. The discriminative strength of MMP-9 and TIMP-1 were compared to that of CA19-9 using receiver operating characteristics curves, area under the curves (AUC), specificity and sensitivity. Results: The sensitivities of MMP-9, TIMP-1 and CA19-9 in detecting pancreatic ductal adenocarcinoma were 58.82%, 47.1% and 86%, respectively, with specificities of 34.6%, 692% and 73%. The AUCs of MMP-9, TIMP-1 and CA19-9 were 050, 0.64 and 0.84, respectively. Combining the three markers did not significantly improve detection of pancreatic ductal adenocarcinoma compared to CA19-9 used alone. Conclusion: Circulating MMP-9 and TIMP-1 were inferior to CA19-9 as markers for detecting pancreatic ductal adenocarcinoma and did not improve the diagnostic accuracy when combined with CA19-9.",

keywords = "Former LIFE faculty, Pancreatic ductal adenocarcinoma, carbohydrate antigen19-9, matrix metalloproteinase 9, MMP-9, tissue inhibitor of metalloproteinases 1, TIMP-1, receiver operating characteristic (ROC) curves",

author = "J{\o}rgensen, {Maiken Thyregod} and Nils Brunner and {Schaffalitzky de Muckadell}, {Ove B.}",

year = "2010",

month = feb,

language = "English",

volume = "30",

pages = "587--592",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

}

TY - JOUR

T1 - Comparison of circulating MMP-9, TIMP-1 and CA19-9 in the detection of pancreatic cancer

AU - Jørgensen, Maiken Thyregod

AU - Brunner, Nils

AU - Schaffalitzky de Muckadell, Ove B.

PY - 2010/2

Y1 - 2010/2

N2 - Background/Aim: The performance of the circulating tumor markers carbohydrate antigen 19-9 (CA19-9), matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of metalloproteinase 1 (TIMP-1) were evaluated separately and in combination for their potential value in detecting pancreatic ductal adenocarcinoma. Patients and Methods: The patients had symptoms of pancreatic cancer. The discriminative strength of MMP-9 and TIMP-1 were compared to that of CA19-9 using receiver operating characteristics curves, area under the curves (AUC), specificity and sensitivity. Results: The sensitivities of MMP-9, TIMP-1 and CA19-9 in detecting pancreatic ductal adenocarcinoma were 58.82%, 47.1% and 86%, respectively, with specificities of 34.6%, 692% and 73%. The AUCs of MMP-9, TIMP-1 and CA19-9 were 050, 0.64 and 0.84, respectively. Combining the three markers did not significantly improve detection of pancreatic ductal adenocarcinoma compared to CA19-9 used alone. Conclusion: Circulating MMP-9 and TIMP-1 were inferior to CA19-9 as markers for detecting pancreatic ductal adenocarcinoma and did not improve the diagnostic accuracy when combined with CA19-9.

AB - Background/Aim: The performance of the circulating tumor markers carbohydrate antigen 19-9 (CA19-9), matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of metalloproteinase 1 (TIMP-1) were evaluated separately and in combination for their potential value in detecting pancreatic ductal adenocarcinoma. Patients and Methods: The patients had symptoms of pancreatic cancer. The discriminative strength of MMP-9 and TIMP-1 were compared to that of CA19-9 using receiver operating characteristics curves, area under the curves (AUC), specificity and sensitivity. Results: The sensitivities of MMP-9, TIMP-1 and CA19-9 in detecting pancreatic ductal adenocarcinoma were 58.82%, 47.1% and 86%, respectively, with specificities of 34.6%, 692% and 73%. The AUCs of MMP-9, TIMP-1 and CA19-9 were 050, 0.64 and 0.84, respectively. Combining the three markers did not significantly improve detection of pancreatic ductal adenocarcinoma compared to CA19-9 used alone. Conclusion: Circulating MMP-9 and TIMP-1 were inferior to CA19-9 as markers for detecting pancreatic ductal adenocarcinoma and did not improve the diagnostic accuracy when combined with CA19-9.

KW - Former LIFE faculty

KW - Pancreatic ductal adenocarcinoma

KW - carbohydrate antigen19-9

KW - matrix metalloproteinase 9

KW - MMP-9

KW - tissue inhibitor of metalloproteinases 1

KW - TIMP-1

KW - receiver operating characteristic (ROC) curves

M3 - Journal article

SN - 0250-7005

VL - 30

SP - 587

EP - 592

JO - Anticancer Research

JF - Anticancer Research

ER -

Comparison of circulating MMP-9, TIMP-1 and CA19-9 in the detection of pancreatic cancer

Abstract

Keywords

UN SDGs

Fingerprint

Cite this